JP2005503123A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005503123A5 JP2005503123A5 JP2002581482A JP2002581482A JP2005503123A5 JP 2005503123 A5 JP2005503123 A5 JP 2005503123A5 JP 2002581482 A JP2002581482 A JP 2002581482A JP 2002581482 A JP2002581482 A JP 2002581482A JP 2005503123 A5 JP2005503123 A5 JP 2005503123A5
- Authority
- JP
- Japan
- Prior art keywords
- thyroid
- nucleic acid
- hyperplasia
- tumor
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 66
- 108020004707 nucleic acids Proteins 0.000 claims 58
- 102000039446 nucleic acids Human genes 0.000 claims 58
- 108090000765 processed proteins & peptides Proteins 0.000 claims 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims 27
- 206010018498 Goitre Diseases 0.000 claims 24
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 24
- 208000013076 thyroid tumor Diseases 0.000 claims 24
- 229920001184 polypeptide Polymers 0.000 claims 23
- 230000006016 thyroid dysfunction Effects 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 19
- 239000003814 drug Substances 0.000 claims 14
- 238000004519 manufacturing process Methods 0.000 claims 13
- 238000000034 method Methods 0.000 claims 13
- 108091030071 RNAI Proteins 0.000 claims 10
- 230000009368 gene silencing by RNA Effects 0.000 claims 10
- 206010020718 hyperplasia Diseases 0.000 claims 10
- 102000053642 Catalytic RNA Human genes 0.000 claims 8
- 108090000994 Catalytic RNA Proteins 0.000 claims 8
- 108091092562 ribozyme Proteins 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 230000000692 anti-sense effect Effects 0.000 claims 7
- 230000003993 interaction Effects 0.000 claims 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 210000001685 thyroid gland Anatomy 0.000 claims 6
- 238000013519 translation Methods 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 230000000295 complement effect Effects 0.000 claims 5
- 238000003745 diagnosis Methods 0.000 claims 5
- 230000002759 chromosomal effect Effects 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 108091023037 Aptamer Proteins 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 238000012216 screening Methods 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims 2
- -1 aptazymes Proteins 0.000 claims 2
- 239000002299 complementary DNA Substances 0.000 claims 2
- 238000011161 development Methods 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000002068 genetic effect Effects 0.000 claims 2
- 230000002390 hyperplastic effect Effects 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- 230000005740 tumor formation Effects 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 208000034951 Genetic Translocation Diseases 0.000 claims 1
- 101000714607 Homo sapiens Carnitine O-acetyltransferase Proteins 0.000 claims 1
- 101000715499 Homo sapiens Catalase Proteins 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000003872 goiter Diseases 0.000 claims 1
- 102000045501 human CAT Human genes 0.000 claims 1
- 210000003917 human chromosome Anatomy 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 210000004882 non-tumor cell Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 230000005945 translocation Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10118452A DE10118452A1 (de) | 2001-04-12 | 2001-04-12 | Nukleinsäuresequenzen von Hyperplasien und Tumoren der Schilddrüse |
| PCT/EP2002/004090 WO2002083727A2 (de) | 2001-04-12 | 2002-04-12 | Nukleinsäuresequenzen von hyperplasien und tumoren der schilddrüse |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005503123A JP2005503123A (ja) | 2005-02-03 |
| JP2005503123A5 true JP2005503123A5 (enExample) | 2005-08-04 |
Family
ID=7681480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002581482A Pending JP2005503123A (ja) | 2001-04-12 | 2002-04-12 | 甲状腺の過形成と腫瘍の核酸配列 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1377607A2 (enExample) |
| JP (1) | JP2005503123A (enExample) |
| AU (1) | AU2002310840A1 (enExample) |
| DE (1) | DE10118452A1 (enExample) |
| WO (1) | WO2002083727A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005011003B9 (de) * | 2004-03-03 | 2009-02-26 | Universität Leipzig | Verfahren und Mittel zur differentiellen Diagnose von Schilddrüsentumoren |
| CA2607185A1 (en) * | 2005-05-04 | 2006-11-09 | Noxxon Pharma Ag | Intracellular active agents |
| JP2013502906A (ja) | 2009-08-31 | 2013-01-31 | アルケド バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 染色体再編成を伴う腫瘍の診断、予後及び治療のためのマイクロｒｎａに基づいた方法及び組成物 |
| US10404099B1 (en) | 2018-02-28 | 2019-09-03 | Corning Optical Communications LLC | Intermediate power supply unit for distributing lower voltage power to remote power distribution systems |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999033982A2 (en) * | 1997-12-23 | 1999-07-08 | Chiron Corporation | Human genes and gene expression products i |
-
2001
- 2001-04-12 DE DE10118452A patent/DE10118452A1/de not_active Withdrawn
-
2002
- 2002-04-12 JP JP2002581482A patent/JP2005503123A/ja active Pending
- 2002-04-12 WO PCT/EP2002/004090 patent/WO2002083727A2/de not_active Ceased
- 2002-04-12 EP EP02735249A patent/EP1377607A2/de not_active Ceased
- 2002-04-12 AU AU2002310840A patent/AU2002310840A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023237051B2 (en) | Oligonucleotide probes and uses thereof | |
| JP5589149B2 (ja) | 癌に関与するポリヌクレオチド配列およびポリペプチド配列 | |
| JP2007506426A5 (enExample) | ||
| WO1999033963A1 (en) | Metastatic cancer regulated gene | |
| CA2488404A1 (en) | Genes and polypeptides relating to human colon cancers | |
| CN107109411A (zh) | 核基因输出的定向增加 | |
| JP2005505274A5 (enExample) | ||
| AU2023254992A1 (en) | CREBBP related cancer therapy | |
| JP2007534725A5 (enExample) | ||
| JP2006518186A5 (enExample) | ||
| US20050170500A1 (en) | Methods for identifying risk of melanoma and treatments thereof | |
| JP2008512984A5 (enExample) | ||
| CN115280153A (zh) | 用于诊断或治疗抗癌药物耐药性的组合物 | |
| JP2005519608A5 (enExample) | ||
| JP2005534295A5 (enExample) | ||
| JP2008502355A5 (enExample) | ||
| JP2005503123A5 (enExample) | ||
| CN111479931B (zh) | 使用基因表达测定预测肽受体放射治疗 | |
| KR102574799B1 (ko) | 마약 중독 또는 금단증상 진단용 바이오마커 조성물 및 마약 중독 또는 금단증상 진단용 키트 | |
| JP2003503704A (ja) | ランゲルハンス島及びβ細胞機能不全に関する方法及び組成物 | |
| US12162874B2 (en) | Peptidomimetic-based antibody surrogate for HER2 | |
| EP4031667B1 (en) | Ca-ix aptamers and diagnostic and therapeutic uses thereof | |
| US20220363767A1 (en) | Hla-h, hla-j, hla-l, hla-v and hla-y as therapeutic and diagnostic targets | |
| JP2007224009A (ja) | 癌の予防・治療剤 | |
| JP2007505825A5 (enExample) |